Literature DB >> 18393322

Vascular biology and pathobiology of the liver: Report of a single-topic symposium.

Yasuko Iwakiri1, Matthew Grisham, Vijay Shah.   

Abstract

Portal hypertension and its complications account for the majority of morbidity and mortality that occurs in patients with cirrhosis. In addition to portal hypertension, a number of other vascular syndromes are also of great importance, especially the ischemia-reperfusion (IR) injury. With the identification of major vascular defects that could account for many of the clinical sequelae of these syndromes, the liver vasculature field has now integrated very closely with the broader vascular biology discipline. In that spirit, the Henry and Lillian Stratton Basic Research Single Topic Conference was held on the topic of Vascular Biology and Pathobiology of the Liver. The course took place approximately 10 years after the first American Association for the Study of Liver Disease (AASLD)-sponsored conference on this topic that occurred in Reston, Virginia. The conference initiated with an introduction to basic vascular cell signaling and then explored vascular biology specifically as it relates to liver cells. Subsequently, specific disease syndromes were discussed in more detail including portal hypertension and IR injury. Finally, clinical and translational sessions focused on emerging therapies and technologies to treat vascular diseases of the liver.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18393322      PMCID: PMC2724750          DOI: 10.1002/hep.22203

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  67 in total

1.  Nitric oxide synthase generates nitric oxide locally to regulate compartmentalized protein S-nitrosylation and protein trafficking.

Authors:  Yasuko Iwakiri; Ayano Satoh; Suvro Chatterjee; Derek K Toomre; Cecile M Chalouni; David Fulton; Roberto J Groszmann; Vijay H Shah; William C Sessa
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-14       Impact factor: 11.205

Review 2.  Angiogenesis and anti-angiogenesis in hepatocellular carcinoma.

Authors:  Domenico Ribatti; Angelo Vacca; Beatrice Nico; Domenico Sansonno; Franco Dammacco
Journal:  Cancer Treat Rev       Date:  2006-07-25       Impact factor: 12.111

Review 3.  The future of GI and liver research: editorial perspectives: II. Modulating leukocyte recruitment to splanchnic organs to reduce inflammation.

Authors:  Claudine S Bonder; Paul Kubes
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2003-05       Impact factor: 4.052

4.  Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve.

Authors:  Jun Yu; Ebo D deMuinck; Zhenwu Zhuang; Mary Drinane; Katalin Kauser; Gabor M Rubanyi; Hu Sheng Qian; Takahisa Murata; Bruno Escalante; William C Sessa
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-25       Impact factor: 11.205

Review 5.  The emerging roles of hydrogen sulfide in the gastrointestinal tract and liver.

Authors:  Stefano Fiorucci; Eleonora Distrutti; Giuseppe Cirino; John L Wallace
Journal:  Gastroenterology       Date:  2006-03-06       Impact factor: 22.682

Review 6.  Protein S-nitrosylation: purview and parameters.

Authors:  Douglas T Hess; Akio Matsumoto; Sung-Oog Kim; Harvey E Marshall; Jonathan S Stamler
Journal:  Nat Rev Mol Cell Biol       Date:  2005-02       Impact factor: 94.444

7.  Vascular tumors in livers with targeted inactivation of the von Hippel-Lindau tumor suppressor.

Authors:  V H Haase; J N Glickman; M Socolovsky; R Jaenisch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-13       Impact factor: 11.205

8.  FK409, a new nitric-oxide donor, suppresses smooth muscle proliferation in the rat model of balloon angioplasty.

Authors:  J Seki; M Nishio; Y Kato; Y Motoyama; K Yoshida
Journal:  Atherosclerosis       Date:  1995-09       Impact factor: 5.162

9.  Functional analysis of zebrafish microfibril-associated glycoprotein-1 (Magp1) in vivo reveals roles for microfibrils in vascular development and function.

Authors:  Eleanor Chen; Jon D Larson; Stephen C Ekker
Journal:  Blood       Date:  2006-02-09       Impact factor: 22.113

10.  Reduced inflammatory response and increased microcirculatory disturbances during hepatic ischemia-reperfusion injury in steatotic livers of ob/ob mice.

Authors:  Tadashi Hasegawa; Yoshiya Ito; Jayanthika Wijeweera; Jie Liu; Ernst Malle; Anwar Farhood; Robert S McCuskey; Hartmut Jaeschke
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2007-02-15       Impact factor: 4.052

View more
  16 in total

Review 1.  Extrahepatic complications to cirrhosis and portal hypertension: haemodynamic and homeostatic aspects.

Authors:  Søren Møller; Jens H Henriksen; Flemming Bendtsen
Journal:  World J Gastroenterol       Date:  2014-11-14       Impact factor: 5.742

2.  Hemodynamics and pharmacokinetics of tezosentan, a dual endothelin receptor antagonist, in patients with cirrhosis.

Authors:  Didier Lebrec; Jaime Bosch; Rajiv Jalan; Francis J Dudley; Rada Jessic; Richard Moreau; Juan Carlos Garcia-Pagan; Rajeshwar P Mookerjee; Eleonora Chiossi; Paul L M Van Giersbergen; Andjela Kusic-Pajic; Jasper Dingemanse
Journal:  Eur J Clin Pharmacol       Date:  2011-11-20       Impact factor: 2.953

Review 3.  Pathophysiology of portal hypertension.

Authors:  Yasuko Iwakiri
Journal:  Clin Liver Dis       Date:  2014-02-25       Impact factor: 6.126

4.  Aquaporin-1 promotes angiogenesis, fibrosis, and portal hypertension through mechanisms dependent on osmotically sensitive microRNAs.

Authors:  Robert C Huebert; Kumaravelu Jagavelu; Helen I Hendrickson; Meher M Vasdev; Juan P Arab; Patrick L Splinter; Christy E Trussoni; Nicholas F Larusso; Vijay H Shah
Journal:  Am J Pathol       Date:  2011-08-18       Impact factor: 4.307

Review 5.  Hepatic sinusoids in liver injury, inflammation, and fibrosis: new pathophysiological insights.

Authors:  Thomas Greuter; Vijay H Shah
Journal:  J Gastroenterol       Date:  2016-03-03       Impact factor: 7.527

Review 6.  Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions.

Authors:  Yasuko Iwakiri; Vijay Shah; Don C Rockey
Journal:  J Hepatol       Date:  2014-06-06       Impact factor: 25.083

7.  Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension.

Authors:  Rajeshwar P Mookerjee; Gautam Mehta; Vairappan Balasubramaniyan; Fatma El Zahraa Mohamed; Nathan Davies; Vikram Sharma; Yasuko Iwakiri; Rajiv Jalan
Journal:  J Hepatol       Date:  2014-08-23       Impact factor: 25.083

Review 8.  Liver fibrosis: Pathophysiology and clinical implications.

Authors:  Jennifer Berumen; Jacopo Baglieri; Tatiana Kisseleva; Kristin Mekeel
Journal:  WIREs Mech Dis       Date:  2020-07-26

9.  Hepatic arterial vasodilation is independent of portal hypertension in early stages of cirrhosis.

Authors:  Miriam Moeller; Antje Thonig; Sabine Pohl; Cristina Ripoll; Alexander Zipprich
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

10.  "Non alcoholic fatty liver disease and eNOS dysfunction in humans".

Authors:  Marcello Persico; Mario Masarone; Antonio Damato; Mariateresa Ambrosio; Alessandro Federico; Valerio Rosato; Tommaso Bucci; Albino Carrizzo; Carmine Vecchione
Journal:  BMC Gastroenterol       Date:  2017-03-07       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.